trial
as of 2026-07-01A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCTId NCT04512066
at a glance
Phase 2 · Completed
Enrollment 287 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2022-06-21
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
287 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-09-08
Primary completion
2022-06-21
Eligibility
ALL · 18 Years · 45 Years
Interventions & indications
Sponsors
Hoffmann-La RocheLead Sponsor
Sites
40 total
Little Rock, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesOrange, United StatesPanorama City, United StatesPico Rivera, United StatesRiverside, United StatesSan Diego, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
287
Phase
PHASE2
Primary Completion Date
2022-06-21
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
indication
indication
indication